Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis (R21)
National Institutes of Health · Opportunity PA-07-022
Multiple Receipt Dates - See Link to Full Announcement for details.
Who can apply
- Public and State institutions of higher education
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Foreign institutions are eligible to apply.
About this opportunity
-The National Cancer Institute (NCI) has identified risk prediction as an area of extraordinary opportunity in NCI s 2006 Plan and Budget Proposal: The Nation's Investment in Cancer Research (http://plan2006.cancer.gov/). To explore this opportunity, the NCI Division of Cancer Control and Population Sciences (DCCPS) and the Division of Cancer Treatment and Diagnosis (DCTD) solicit applications for research projects to develop, apply, and evaluate new and existing cancer risk and prognostic prediction models for use by researchers, clinicians, and the general public. -The purpose of this Funding Opportunity Announcement (FOA) is to encourage clinicians, epidemiologists, geneticists, statisticians, and translational researchers working in the field of cancer control and prevention to improve existing models for cancer risk and prognosis by developing innovative research projects that use existing data; develop new models for cancer risk and prognosis; and validate new models and evaluate their utility in research and clinic settings. Applications that are focused on the identification and characterization of prognostic/diagnostic markers are NOT responsive to this FOA. -This FOA is designed to provide a mechanism of support for investigators to address two major challenges in model development, which are: integrating diverse types of data (e.g., clinical, demographic, pathologic, environmental, epidemiologic, outcomes, and genetic data from varied data marts or warehouses); and ensuring adequate validation (i.e., using multiple separate populations to define sensitivity, specificity, and positive and negative predictive values).
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | National Institutes of Health | August 18, 2026 23d left | — | Nonprofits |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | $499k | Nonprofits |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |